Management of hepatitis B: our practice and how it relates to the guidelines.
about
KASL clinical practice guidelines: management of chronic hepatitis BTreatment of rheumatic diseases and hepatitis B virus coinfectionAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.A novel system for predicting liver histopathology in patients with chronic hepatitis BImmune Tolerant Chronic Hepatitis B: The Unrecognized RisksSerum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferaseAntiviral treatment among pregnant women with chronic hepatitis B.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Personalized treatment of hepatitis B.Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate CellsEpidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.Present and future therapies of hepatitis B: From discovery to cureLong-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection.Towards the elimination and eradication of hepatitis B.Treatment of Hepatitis B: A Concise Review.New universal primers for genotyping and resistance detection of low HBV DNA levels.Determination of hepatitis B phenotype using biochemical and serological markers.Chronic hepatitis B: A wave of new therapies on the horizon.Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Estimated Annual Perinatal Hepatitis B Virus Infections in the United States, 2000-2009.Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings.Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.Effects of interaction between genetic variants in human leukocyte antigen DQ and granulysin genes in Chinese Han subjects infected with hepatitis B virus.Hepatitis B cure: From discovery to regulatory approval.Recurrent hepatocellular carcinoma: it's the virus!Single nucleotide polymorphisms in ZNF208 are associated with increased risk for HBV in Chinese people.Hepatitis B Virus Genotype C is Predominant in Myanmar.Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.Should AFP (or any biomarkers) be used for HCC surveillance?Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model.Prevalence of Hepatitis B and C virus infection and their co-relation with hematological and hepatic parameters in subjects undergoing Premarital Screening in the Jazan Region, Kingdom of Saudi Arabia.Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B
P2860
Q26752475-201E3758-0D28-4721-8021-7997764901F4Q28084305-54F920D2-04B8-485D-9DD4-94572BDF0811Q30391932-AD1DA19F-8AB2-48D1-ACC5-A0D4A9B85C5BQ33621252-A6A14E2B-5811-41E9-AED0-E48F4C1DCA31Q33753902-AA21EBC0-F9A4-464E-B8B0-022FEA703874Q33765826-FE39E0A4-5780-4914-95F3-967F957257BAQ34762578-8B6766AC-9410-4E3C-87A0-64588F4D6253Q35118955-BB7AED76-E317-4645-9F00-24348769C975Q35231805-94D499A0-D435-4520-8FF6-6CB31C5805C6Q35694422-1CAA8172-4D3E-40EE-8003-B919ACF03320Q35885524-9B153FD0-10B0-4623-B3B6-6CB055F93830Q36324370-614D4634-A857-4F43-A47E-1F97D50D9AB7Q36378278-AE832C10-C404-499B-A4DD-A169CE303996Q36401963-5232F226-A53D-483C-A887-F38B4A8B19B1Q37098214-A6A37A20-8F12-46FB-AE46-F3F4AD8F33BEQ37620340-586B4A50-C2BF-4A8F-A568-9C527B81BEE5Q37726789-0496858E-6EA9-4239-97B2-BEFC0FC10BFBQ38383869-E1AC22B2-3CFF-456D-82ED-0491E2F21DEFQ38538107-106CEFD2-0DB5-4363-AF44-783737F2AC37Q38998819-C704C6A7-381C-4E4F-A8D6-F5420A7283E5Q39377075-9B37AAF2-03EE-4DE9-A3AD-449E1CFC218BQ40189344-2DA41B81-1497-49AF-B977-9023EAB65B46Q40500692-98DC3138-D68F-45DB-9E06-E7921EF9E843Q40638498-CB14533C-2508-4D2A-B326-5C397F849A83Q40956888-923691F2-0A15-46D4-B6FD-BB3FD4C7F9B9Q41468537-6B64999A-1EC9-4D8D-AE0E-88C4D994C74DQ41508470-6D41FC9A-EF69-48E3-B5DE-A022DD6CA945Q41952398-D6CB3A3D-DDFE-41E2-A630-FE72EE972035Q42946913-6DE73B3E-BD50-4A22-AF96-F3A340C53278Q47551618-EA27A4F8-DD6D-4D89-8AE8-52FA41C7F9A0Q47560474-A6DDAD6A-EAEF-461C-A8F8-0986EECFBC27Q49997050-70130FA1-5C21-48F0-82BF-4EF8E88104D2Q50223186-5434B29D-EB21-4DFC-AA07-0C5DC21C6C6DQ55315556-EB55CDA9-7D86-4087-8EFF-B50EE278A36BQ55357425-54CD8015-AF67-466E-9C8B-08D731784764Q57482199-D36F1F5E-462A-4571-8AEF-609B00A0FA9F
P2860
Management of hepatitis B: our practice and how it relates to the guidelines.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of hepatitis B: our practice and how it relates to the guidelines.
@en
type
label
Management of hepatitis B: our practice and how it relates to the guidelines.
@en
prefLabel
Management of hepatitis B: our practice and how it relates to the guidelines.
@en
P2093
P1476
Management of hepatitis B: our practice and how it relates to the guidelines.
@en
P2093
Anna S Lok
Nizar Talaat
Suna Yapali
P356
10.1016/J.CGH.2013.04.036
P407
P577
2013-05-06T00:00:00Z